Trastuzumab-deruxtecan (T-DXd) is an antibody-drug conjugate composed of an anti-HER2 antibody, a cleavable tetrapeptide-based linker and a cytotoxic topoisomerase I inhibitor. Recent studies have been evaluating its efficacy in patients with advanced HER2+ breast cancer showing a significant increase in both PFS and OS. T-DXd is destined to become in the following years the standard of care in increasingly early lines of therapy for the treatment of advanced HER2+ breast cancer and it may also play an important role in the management of HER2-low expressing breast cancer. Given its recent development, as of today there are only few data available in terms of toxicities and efficacy outside clinical trials.
Trastuzumab-deruxtecan (T-DXd) è un coniugato farmaco-anticorpo costituito da un anticorpo monoclonale anti-HER2, un linker tetrapeptidico clivabile ed un inibitore della topoisomerasi I. Recenti studi hanno valutato l’efficacia di tale farmaco nelle pazienti con neoplasia della mammella HER2+ in stadio avanzato dimostrando di aumentare significativamente la PFS e l’OS. T-DXd è destinato a diventare nei prossimi anni lo standard di terapia in linee sempre più precoci di trattamento per tumori HER2 + in stadio avanzato e potrebbe svolgere un ruolo significativo anche nella gestione delle neoplasie della mammella con bassa espressione di HER2. Dato il suo recente sviluppo sono ad oggi disponibili pochi dati in merito alla sua tossicità ed efficacia al di fuori degli studi clinici.
Trattamento con Trastuzumab - deruxtecan in pazienti con carcinoma mammario HER - 2 positivo in stadio avanzato
PANOZZO, MARCO PELLEGRINO
2021/2022
Abstract
Trastuzumab-deruxtecan (T-DXd) is an antibody-drug conjugate composed of an anti-HER2 antibody, a cleavable tetrapeptide-based linker and a cytotoxic topoisomerase I inhibitor. Recent studies have been evaluating its efficacy in patients with advanced HER2+ breast cancer showing a significant increase in both PFS and OS. T-DXd is destined to become in the following years the standard of care in increasingly early lines of therapy for the treatment of advanced HER2+ breast cancer and it may also play an important role in the management of HER2-low expressing breast cancer. Given its recent development, as of today there are only few data available in terms of toxicities and efficacy outside clinical trials.File | Dimensione | Formato | |
---|---|---|---|
Panozzo_MarcoPellegrino.pdf
accesso aperto
Dimensione
3.26 MB
Formato
Adobe PDF
|
3.26 MB | Adobe PDF | Visualizza/Apri |
The text of this website © Università degli studi di Padova. Full Text are published under a non-exclusive license. Metadata are under a CC0 License
https://hdl.handle.net/20.500.12608/30696